Clinical Trial Update: Safety and Preliminary Protective Efficacy of Genetically Attenuated GA2 Parasites. [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/Phase 2 clinical trial evaluating safety and preliminary protective efficacy of genetically attenuated GA2 parasites for Plasmodium falciparum malaria.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plasmodium Falciparum Malaria

Drugs mentioned

• GA2 parasites (genetically attenuated) (genetically attenuated Plasmodium falciparum parasites)

Snippet

Sponsor: Leiden University Medical Center | Conditions: Plasmodium Falciparum Malaria | Phase 1, Phase 2 | Status: COMPLETED